We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...

Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at ...

Pfizer has had a difficult time in recent years as demand for its coronavirus products declined. The company’s share price has reflected the tough times, falling more than 50% over three years.

Kennedy Jr., a vaccine skeptic, as head of Health and Human Services (HHS ... s stock following the latest dip. Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined steeply ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...

Albert Bourla, Pfizer Chairman and Chief Executive Officer ... technology systems and infrastructure (including cloud services); any business disruption, theft of confidential or proprietary ...

Pfizer said a late-stage study of its sasanlimab ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU ...

The company's adjusted gross margin of 70% in Q3-24 reflects challenges from an unfavorable mix of COVID-19 products and royalty expenses but highlights ongoing cost control measures. Pfizer ...